Literature DB >> 20146723

Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid.

K Cilliers1, D Labadarios1, H S Schaaf1, M Willemse1, J S Maritz1, C J Werely1, G Hussey1, P R Donald1.   

Abstract

AIM: Little is known about pyridoxine nutriture of children treated with isoniazid (INH) regimens. This study documents plasma pyridoxal 5'-phosphate (PLP) concentrations in children, HIV-infected and HIV-uninfected, receiving INH regimens.
METHODS: Children from the Western Cape of South Africa hospitalized for tuberculosis (TB) management were studied. Plasma PLP concentrations were determined on enrolment, 1-month after commencing TB treatment, and again after 4-month's treatment. The children received a supplement meeting pyridoxine requirements.
RESULTS: Nineteen HIV-infected and 33 HIV-uninfected children received INH (dosage range 4-20 mg/kg) daily. Mean PLP plasma concentrations on enrolment were 8.32 (SD 6.75) ng/mL and 11.28 (SD 3.02) ng/mL in HIV-infected and HIV-uninfected children, respectively (p = 0.11) and after 4-month's treatment 6.75 (SD 2.71) ng/mL and 14.76 (SD 7.96) ng/mL (p < 0.001). On enrolment 9 (50%) HIV-infected and 5 (15%) HIV-uninfected children (p = 0.016) had suboptimal PLP concentrations (<6 ng/mL); after 4-month's treatment 8 (42%) and 2 (6%) (p = 0.004).
CONCLUSION: Plasma PLP concentrations in children treated for TB were low on enrolment in HIV-infected and HIV-uninfected children; after 4-month's treatment low values were still common in HIV-infected children. Additional pyridoxine supplementation of malnourished children treated for tuberculosis is advisable, particularly those HIV-infected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146723     DOI: 10.1111/j.1651-2227.2010.01696.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.

Authors:  Christopher Trent Brewer; Lei Yang; Anne Edwards; Yan Lu; Jonathan Low; Jing Wu; Richard E Lee; Taosheng Chen
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

2.  Drug-resistant tuberculosis: pediatric guidelines.

Authors:  Navaneetha Pandian Poorana Ganga Devi; Soumya Swaminathan
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

3.  Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.

Authors:  Hind Satti; Megan M McLaughlin; David B Omotayo; Salmaan Keshavjee; Mercedes C Becerra; Joia S Mukherjee; Kwonjune J Seung
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

Review 4.  Severe acute malnutrition and infection.

Authors:  Kelsey D J Jones; James A Berkley
Journal:  Paediatr Int Child Health       Date:  2014-12       Impact factor: 1.990

Review 5.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

6.  Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India.

Authors:  Faisal Imam; Manju Sharma; Khalid Umer Khayyam; Mohammad Rashid Khan; Mohammad Daud Ali; Wajhul Qamar
Journal:  Saudi Pharm J       Date:  2020-04-19       Impact factor: 4.330

7.  Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid.

Authors:  Christopher Trent Brewer; Kiran Kodali; Jing Wu; Timothy I Shaw; Junmin Peng; Taosheng Chen
Journal:  Cells       Date:  2020-07-09       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.